footandmouth
diseas
fmd
highli
contagi
viral
diseas
clovenhoof
anim
signific
econom
consequ
affect
countri
current
avail
vaccin
fmd
provid
protect
day
postvaccin
altern
method
control
spread
fmd
viru
fmdv
outbreak
applic
antivir
agent
henc
import
identifi
effect
antivir
agent
fmdv
infect
studi
found
mizoribin
potent
antivir
activ
fmdv
replic
cell
timeofdrugaddit
assay
demonstr
mizoribin
function
earli
stage
replic
moreov
mizoribin
also
show
antivir
effect
fmdv
vivo
summari
result
reveal
mizoribin
could
potenti
antivir
drug
fmdv
footandmouth
diseas
fmd
one
econom
social
devast
diseas
affect
clovenhoof
anim
infecti
agent
footandmouth
diseas
viru
fmdv
member
aphthoviru
genu
picornavirida
famili
contain
singlestrand
positivesens
rna
genom
nucleotid
antigen
variabl
viru
fmdv
consist
seven
serotyp
c
asia
south
african
territori
larg
number
subtyp
gener
slaughter
fmdvinfectedexpos
fmdvsuscept
anim
restrict
anim
movement
case
vaccin
fmdv
slaughter
anim
use
control
measur
potenti
outbreak
diseasefre
area
although
inactiv
fmd
vaccin
avail
sinc
earli
new
novel
vaccin
continu
develop
offer
littl
crossprotect
variou
serotyp
subtyp
fmdv
addit
vaccin
provid
complet
clinic
protect
seven
day
postvaccin
therefor
need
develop
effect
safe
altern
antivir
strategi
fmdv
mizoribin
imidazol
nucleosid
figur
use
immunosuppress
agent
treatment
renal
transplant
autoimmun
diseas
steroidresist
nephrot
syndrom
countri
owe
antiprolif
activ
b
lymphocyt
drug
could
phosphoryl
adenosin
kinas
convert
mizoribin
monophosph
replic
dna
rna
virus
cytomegaloviru
respiratori
syncyti
viru
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
bovin
viral
diarrhea
viru
bvdv
vaccinia
viru
influenza
viru
type
b
herpesvirus
combin
acyclovir
howev
antivir
activ
mizoribin
fmdv
yet
investig
henc
studi
antivir
effect
mizoribin
fmdv
evalu
vitro
use
cell
confirm
vivo
use
suckl
mice
figur
illustr
result
mt
assay
shown
figur
mizoribin
present
littl
cytotox
cell
cell
viabil
mizoribin
concentr
respect
cytotox
concentr
mizoribin
estim
cell
inhibitori
effect
mizoribin
fmdv
infect
cell
calcul
measur
cell
viabil
use
result
mt
assay
indic
figur
inhibit
rate
approxim
cell
treat
mizoribin
respect
wherea
lower
mizoribin
concentr
demonstr
limit
inhibitori
effect
fmdv
si
valu
calcul
respect
interestingli
mizoribin
also
display
activ
anoth
fmdv
strain
si
valu
figur
data
support
potenti
broadspectrum
activ
mizoribin
rna
virus
figur
illustr
result
mt
assay
shown
figur
mizoribin
present
littl
cytotox
cell
cell
viabil
mizoribin
concentr
respect
cytotox
concentr
cc
mizoribin
estim
cell
inhibitori
effect
mizoribin
fmdv
infect
cell
calcul
measur
cell
viabil
use
result
mt
assay
indic
figur
inhibit
rate
approxim
cell
treat
mizoribin
respect
wherea
lower
mizoribin
concentr
demonstr
limit
inhibitori
effect
fmdv
ic
si
valu
calcul
respect
interestingli
mizoribin
also
display
activ
anoth
fmdv
strain
ic
si
valu
figur
data
support
potenti
broadspectrum
activ
mizoribin
rna
virus
transcript
fmdv
mrna
significantli
reduc
mizoribin
treatment
rel
dmso
control
group
figur
consist
mrna
express
immunofluoresc
assay
ifa
reveal
mizoribin
inhibit
express
fmdv
protein
dosedepend
manner
figur
concentr
show
protect
cpe
concentr
chosen
studi
transcript
fmdv
mrna
significantli
reduc
mizoribin
treatment
rel
dmso
control
group
figur
consist
mrna
express
immunofluoresc
assay
ifa
reveal
mizoribin
inhibit
express
fmdv
protein
dosedepend
manner
figur
concentr
show
protect
cpe
concentr
chosen
studi
subsequ
antivir
efficaci
mizoribin
evalu
variou
interv
postfmdv
infect
found
viral
mrna
protein
express
continu
inhibit
differ
time
point
h
treatment
mizoribin
howev
signific
differ
observ
h
postinfect
hpi
control
group
figur
taken
togeth
result
suggest
mizoribin
exhibit
potent
antivir
activ
fmdv
cell
earli
stage
viral
infect
supernat
use
viral
rna
quantif
use
qpcr
express
valu
rel
calcul
use
method
cpe
cytopath
effect
statist
signific
differ
indic
asterisk
p
p
transcript
fmdv
mrna
significantli
reduc
mizoribin
treatment
rel
dmso
control
group
figur
consist
mrna
express
immunofluoresc
assay
ifa
reveal
mizoribin
inhibit
express
fmdv
protein
dosedepend
manner
figur
concentr
show
protect
cpe
concentr
chosen
studi
subsequ
antivir
efficaci
mizoribin
evalu
variou
interv
postfmdv
infect
found
viral
mrna
protein
express
continu
inhibit
differ
time
point
h
treatment
mizoribin
howev
signific
differ
observ
h
postinfect
hpi
control
group
figur
taken
togeth
result
suggest
mizoribin
exhibit
potent
antivir
activ
fmdv
cell
earli
stage
viral
infect
subsequ
antivir
efficaci
mizoribin
evalu
variou
interv
postfmdv
infect
found
viral
mrna
protein
express
continu
inhibit
differ
time
point
h
treatment
mizoribin
howev
signific
differ
observ
h
postinfect
hpi
control
group
figur
taken
togeth
result
suggest
mizoribin
exhibit
potent
antivir
activ
fmdv
cell
earli
stage
viral
infect
vc
repres
cell
treat
dmso
without
mizoribin
valu
repres
mean
standard
deviat
three
independ
experi
asterisk
indic
signific
differ
mocktreat
drugtreat
cell
p
dehydrogenas
impdh
requir
de
novo
purin
nucleotid
synthesi
inhibit
lead
deplet
intracellular
gtp
pool
investig
effect
mizoribin
purin
synthesi
fmdv
serial
dilut
guanosin
ad
infect
cell
treat
mizoribin
guanosin
effect
mizoribin
significantli
attenu
antifmdv
effect
mizoribin
dosedepend
manner
figur
data
indic
mizoribin
activ
fmdv
involv
inhibit
impdhdepend
purin
synthesi
monophosph
dehydrogenas
impdh
requir
de
novo
purin
nucleotid
synthesi
inhibit
lead
deplet
intracellular
gtp
pool
investig
effect
mizoribin
purin
synthesi
fmdv
serial
dilut
guanosin
ad
infect
cell
treat
mizoribin
guanosin
effect
mizoribin
significantli
attenu
antifmdv
effect
mizoribin
dosedepend
manner
figur
data
indic
mizoribin
activ
fmdv
involv
inhibit
impdhdepend
purin
synthesi
vc
repres
cell
treat
dmso
without
mizoribin
valu
repres
mean
standard
deviat
three
independ
experi
asterisk
indic
signific
differ
mocktreat
drugtreat
cell
p
dehydrogenas
impdh
requir
de
novo
purin
nucleotid
synthesi
inhibit
lead
deplet
intracellular
gtp
pool
investig
effect
mizoribin
purin
synthesi
fmdv
serial
dilut
guanosin
ad
infect
cell
treat
mizoribin
guanosin
effect
mizoribin
significantli
attenu
antifmdv
effect
mizoribin
dosedepend
manner
figur
data
indic
mizoribin
activ
fmdv
involv
inhibit
impdhdepend
purin
synthesi
suckl
mice
pretreat
subcutan
inject
mizoribin
pb
neck
infect
fmdv
determin
antivir
activ
mizoribin
vivo
solventtr
mice
die
within
h
ld
challeng
contrast
delay
death
postinfect
note
mizoribinetr
group
mice
die
within
h
viral
challeng
overal
death
time
mice
treat
mizoribin
delay
h
compar
control
signific
differ
mous
surviv
note
treatment
group
control
p
figur
suckl
mice
pretreat
subcutan
inject
mizoribin
pb
neck
infect
fmdv
determin
antivir
activ
mizoribin
vivo
solventtr
mice
die
within
h
challeng
contrast
delay
death
postinfect
note
mizoribinetr
group
mice
die
within
h
viral
challeng
overal
death
time
mice
treat
mizoribin
delay
h
compar
control
signific
differ
mous
surviv
note
treatment
group
control
p
figur
furthermor
signific
histopatholog
damag
observ
heart
tissu
fmdvinfect
mice
includ
consider
myocardi
interstiti
hemorrhag
myocardi
fibronectin
degener
extens
inflammatori
cell
infiltr
indic
black
arrow
figur
addit
myocardi
fiber
edema
incomplet
fibrou
structur
also
observ
howev
mice
treat
mizoribin
show
mild
histopatholog
chang
small
amount
inflammatori
cell
infiltr
heart
figur
intriguingli
although
fmdv
antigen
detect
heart
tissu
mizoribinetr
control
mice
statist
signific
figur
find
suggest
histopatholog
damag
may
main
caus
death
result
fmdv
infect
mizoribin
effect
allevi
effect
furthermor
signific
histopatholog
damag
observ
heart
tissu
fmdvinfect
mice
includ
consider
myocardi
interstiti
hemorrhag
myocardi
fibronectin
degener
extens
inflammatori
cell
infiltr
indic
black
arrow
figur
addit
myocardi
fiber
edema
incomplet
fibrou
structur
also
observ
howev
mice
treat
mizoribin
show
mild
histopatholog
chang
small
amount
inflammatori
cell
infiltr
heart
figur
intriguingli
although
fmdv
antigen
detect
heart
tissu
mizoribinetr
control
mice
statist
signific
figur
find
suggest
histopatholog
damag
may
main
caus
death
result
fmdv
infect
mizoribin
effect
allevi
effect
fmdv
exhibit
high
mutat
rate
produc
signific
econom
loss
affect
countri
import
adopt
effect
measur
control
viru
demonstr
mizoribin
produc
tumorigen
gonad
suppress
effect
exert
low
bone
marrow
inhibit
hepatotox
outcom
use
treatment
renal
diseas
human
thu
consid
safe
reliabl
accept
efficaci
mizoribin
human
might
also
employ
treatment
anim
diseas
fmdv
exhibit
high
mutat
rate
produc
signific
econom
loss
affect
countri
import
adopt
effect
measur
control
viru
demonstr
mizoribin
produc
tumorigen
gonad
suppress
effect
exert
low
bone
marrow
inhibit
hepatotox
outcom
use
treatment
renal
diseas
human
thu
consid
safe
reliabl
accept
efficaci
mizoribin
human
might
also
employ
treatment
anim
diseas
best
knowledg
present
studi
first
report
antivir
effect
mizoribin
fmdv
vitro
vivo
use
mt
assay
cytotox
mizoribin
determin
weak
cc
valu
higher
furthermor
mizoribin
show
signific
antifmdv
activ
type
fmdv
strain
also
type
fmdv
si
valu
respect
result
indic
mizoribin
could
better
drug
prevent
fmdv
infect
moreov
qpcr
ifa
find
reveal
mizoribin
significantli
inhibit
viral
mrna
fmdv
protein
level
understand
preliminari
antivir
mechan
mizoribin
timeofdrugaddit
assay
perform
result
demonstr
mizoribin
mainli
function
earli
stage
infect
report
antivir
activ
mizoribin
involv
inhibit
impdh
essenti
enzym
synthesi
guanosin
monophosph
inosin
monophosph
de
novo
pathway
similarli
present
studi
antivir
activ
mizoribin
fmdv
found
attenu
guanosin
supplement
anim
experi
demonstr
mizoribin
inhibitori
effect
fmdv
vivo
treatment
mizoribin
significantli
prolong
surviv
fmdvinfect
suckl
mice
although
vivo
result
show
signific
increas
surviv
rate
infect
mice
delay
death
allevi
histopatholog
chang
suggest
inhibitori
effect
mizoribin
viral
replic
overal
weak
cytotox
strong
antivir
activ
mizoribin
vitro
vivo
favor
potenti
clinic
applic
treatment
viral
infect
combin
treatment
strategi
propos
enhanc
efficaci
antivir
agent
advantag
overcom
viral
mechan
resist
antivir
treatment
demonstr
mizoribin
enhanc
activ
acyclovir
combin
mizoribin
acyclovir
result
almost
complet
inhibit
viral
replic
thu
combin
therapi
acyclovir
mizoribin
could
exploit
treatment
genit
infect
herpesvirus
moreov
mizoribin
report
activ
replic
bvdv
madindarbi
bovin
kidney
mdbk
cell
combin
interferon
ifn
mizoribin
note
synergist
inhibit
bvdv
replic
bovin
kidney
cell
regard
fmd
fmdv
demonstr
sensit
ifn
ifnbas
strategi
establish
effici
biotherapeut
option
fmdv
similarli
combin
antivir
agent
sirna
ribavirin
ifn
determin
produc
enhanc
antivir
effect
fmdv
therefor
futur
studi
must
investig
whether
combin
ifn
mizoribin
could
produc
increas
inhibitori
effect
fmdv
replic
vitro
vivo
conclus
best
author
knowledg
present
studi
first
demonstr
mizoribin
suppress
fmdv
replic
vitro
well
prolong
surviv
suckl
mice
vivo
suggest
potenti
applic
drug
antivir
regimen
fmd
treatment
find
studi
may
warrant
investig
efficaci
safeti
combin
use
mizoribin
antivir
agent
vitro
vivo
thirtytwo
twoand
threedayold
balbc
mice
weigh
g
use
investig
efficaci
mizoribin
vivo
anim
trial
perform
biosafeti
laboratori
approv
anim
ethic
committe
lanzhou
veterinari
research
institut
chines
academi
agricultur
scienc
fmdv
type
strain
use
viral
challeng
cytotox
mizoribin
evalu
use
mt
assay
briefli
cell
seed
well
plate
contain
complet
medium
follow
day
cell
incub
mizoribin
variou
concentr
h
control
cell
treat
dmso
treatment
supernat
discard
cell
wash
three
time
dmem
ad
well
along
mt
solut
incub
addit
h
c
optic
densiti
well
nm
determin
use
micropl
reader
biorad
hercul
ca
usa
cell
viabil
express
percentag
absorb
treat
cell
control
cell
antivir
activ
mizoribin
fmdv
determin
use
mtsbase
cytopath
effect
cpe
inhibit
assay
briefli
viral
suspens
tcid
ad
cell
monolay
incub
h
cell
wash
three
time
dmem
serial
dilut
mizoribin
solut
ad
well
eight
well
concentr
plate
incub
c
co
h
maximum
cpe
note
viru
control
group
vc
cell
viabil
measur
use
mt
assay
describ
earlier
percentag
inhibit
associ
mizoribin
concentr
normal
respect
vc
viru
inhibit
rate
calcul
follow
inhibit
rate
optic
densiti
mizoribin
group
optic
densiti
vc
optic
densiti
cell
control
group
optic
densiti
vc
supernat
well
collect
viral
mrna
analyz
use
qpcr
inhibitori
concentr
ic
valu
calcul
graphpad
softwar
version
la
jolla
ca
usa
monolay
cell
seed
plate
infect
tcid
fmdv
c
h
portion
mizoribin
supplement
serial
dilut
guanosin
ad
incub
h
incub
viral
protein
gene
express
assess
western
blot
analysi
qpcr
respect
cell
incub
tcid
h
subsequ
virus
remov
medium
replac
mizoribin
ad
cell
infect
co
postinfect
h
h
incub
fmdv
mrna
protein
cell
determin
qpcr
western
blot
analysi
respect
express
level
fmdv
mrna
determin
realtim
pcr
previous
report
briefli
total
rna
cell
extract
use
trizol
reagent
rna
use
revers
transcript
reaction
use
rt
reagent
kit
contain
gdna
eras
follow
manufactur
instruct
reaction
mixtur
realtim
pcr
compris
dilut
cdna
primer
sybr
green
master
mix
final
volum
amplif
condit
follow
c
follow
cycl
c
c
c
dissoci
curv
gener
analyz
individu
pcr
product
cycl
express
level
fmdv
mrna
gene
normal
porcin
mrna
analys
rel
gene
express
data
perform
use
method
western
blot
analysi
cell
lyse
pierc
ripa
cell
lysat
resolv
separ
sdspage
transfer
polyvinyliden
fluorid
membran
membran
probe
primari
antibodi
fmdv
protein
dilut
detect
viru
replic
monoclon
antibodi
dilut
use
load
control
membran
incub
goat
antimous
antirabbit
conjug
horseradish
peroxidas
h
room
temperatur
examin
ecl
western
blot
substrat
determin
antivir
activ
mizoribin
indirect
immunofluoresc
assay
ifa
perform
previous
describ
minor
modif
cell
seed
plate
concentr
cellswel
incub
one
day
subsequ
cell
incub
tcid
fmdv
h
mizoribin
dilut
indic
concentr
ad
cell
remov
viral
inoculum
h
incub
cell
wash
thrice
pb
fix
paraformaldehyd
min
paraformaldehyd
remov
absolut
methanol
ad
cell
incub
min
subsequ
cell
wash
pb
block
use
block
buffer
pb
supplement
triton
fb
rabbit
hyperimmun
serum
rais
type
fmdv
use
probe
type
fmdv
peroxidaseconjug
goat
antirabbit
igg
h
l
employ
secondari
antibodi
final
cell
counterstain
dapi
view
fluoresc
microscop
nikon
eclips
fluoresc
microscop
yokagawa
electr
corpor
tokyo
japan
specificpathogenfre
threedayold
kunm
suckl
mice
inocul
mizoribin
dissolv
dmso
tween
ml
pb
subcutan
neck
inject
neg
control
inocul
pb
h
viral
challeng
perform
intraderm
inject
lethal
dose
ld
fmdv
serotyp
subcutan
neck
region
mice
anim
monitor
five
day
logrank
test
perform
statist
analysi
use
graphpad
softwar
h
postinfect
suckl
mice
euthan
process
histolog
immunohistochem
investig
histopatholog
analysi
heart
tissu
fix
paraformaldehyd
solut
embed
paraffin
cut
thick
section
standard
hematoxylin
eosin
h
e
stain
regard
immunohistochem
ihc
studi
fmdv
antigen
detect
follow
thick
paraffinembed
tissu
section
deparaffin
treat
methanolhydrogen
peroxid
min
heatinduc
antigen
retriev
sodium
citrat
buffer
ph
min
rabbit
hyperimmun
serum
rais
type
fmdv
use
primari
antibodi
tissu
section
process
splink
detect
kit
min
stain
dab
min
room
temperatur
wash
tissu
section
counterstain
mount
examin
digit
microscop
motic
xiamen
china
photograph
optic
densiti
tissu
section
determin
imagepro
plu
softwar
media
cybernet
rockvil
md
usa
data
express
mean
standard
deviat
sd
least
three
independ
experi
oneway
anova
use
analyz
differ
mizoribin
control
group
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
version
signific
differ
defin
p
select
index
si
cc
ec
